Research programme: anti-cancer immunomodulators - Yuhan CorporationAlternative Names: YH14810
Latest Information Update: 13 Jan 2016
At a glance
- Originator Yuhan
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jan 2016 Discontinued - Preclinical for Cancer in South Korea (Parenteral)
- 16 Dec 2014 Preclinical development is ongoing in South Korea
- 20 Aug 2012 Preclinical trials in Cancer in South Korea (Parenteral)